MAIA Biotechnology Announces Underwritten Public Offering of Common Stock and Warrants for Cancer Immunotherapies

MAIA Biotechnology has commenced an underwritten public offering of common stock and pre-funded warrants. Konik Capital Partners LLC is the sole book-running manager for the offering. The net proceeds from the offering will be used for clinical trials and general corporate purposes. A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on its website. Interested parties should read the documents in their entirety before investing.